Bernardo Kaplan Moscovici1, Ricardo Holzchuh2, Fernando Eiji Sakassegawa-Naves2, Diego Ricardo Hoshino-Ruiz2, Marcos Bottene Villa Albers2, Ruth Miyuki Santo3, Richard Yudi Hida2. 1. Department of Ophthalmology, University of São Paulo, School of Medicine (Hospital das Clínicas of da Universidade de São Paulo-São Paulo - HC-USP), Brazil; Department of Ophthalmology, Santa Casa de São Paulo, Brazil. Electronic address: bernardokaplan@yahoo.com.br. 2. Department of Ophthalmology, University of São Paulo, School of Medicine (Hospital das Clínicas of da Universidade de São Paulo-São Paulo - HC-USP), Brazil; Department of Ophthalmology, Santa Casa de São Paulo, Brazil. 3. Department of Ophthalmology, University of São Paulo, School of Medicine (Hospital das Clínicas of da Universidade de São Paulo-São Paulo - HC-USP), Brazil.
Abstract
OBJECTIVE: To describe the clinical efficacy of the treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop. DESIGN: Prospective double-blind randomized study. SETTING: Institutional outpatient clinic. PARTICIPANTS: Forty-eight eyes of twenty-four patients with dry eye related to Sjögren syndrome were enrolled in this study. The patients were randomized in 2 groups: tacrolimus (n=14) and vehicle (n=10) group. INTERVENTION: The tacrolimus group received a vial containing tacrolimus 0.03% (almond oil as vehicle) and the other group received the almond oil vehicle. All patients were instructed to use the eye drops every 12h in the lower conjunctival sac. MAIN OUTCOME MEASURES: Schirmer I test, break-up-time (BUT), corneal fluorescein and Rose Bengal staining scores were evaluated in all patients one day before the treatment (baseline), 7, 14, 28 and 90 days after treatment with the eye drops. RESULTS: The average fluorescein and Rose Bengal scores improved statistically after 7 days of treatment and even more after 90 days. The average Schirmer I and BUT values were unchanged after 7, 14 and 21 days but did show an improvement relative to baseline after 28 days of treatment. Schirmer I, BUT, fluorescein and Rose Bengal did not show any statistical significance in the vehicle group. CONCLUSION:Topical 0.03% tacrolimus eye drop improved tear stability and ocular surface status in cases of inflammatory or SS-related dry eye. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01850979.
RCT Entities:
OBJECTIVE: To describe the clinical efficacy of the treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop. DESIGN: Prospective double-blind randomized study. SETTING: Institutional outpatient clinic. PARTICIPANTS: Forty-eight eyes of twenty-four patients with dry eye related to Sjögren syndrome were enrolled in this study. The patients were randomized in 2 groups: tacrolimus (n=14) and vehicle (n=10) group. INTERVENTION: The tacrolimus group received a vial containing tacrolimus 0.03% (almond oil as vehicle) and the other group received the almond oil vehicle. All patients were instructed to use the eye drops every 12h in the lower conjunctival sac. MAIN OUTCOME MEASURES: Schirmer I test, break-up-time (BUT), corneal fluorescein and Rose Bengal staining scores were evaluated in all patients one day before the treatment (baseline), 7, 14, 28 and 90 days after treatment with the eye drops. RESULTS: The average fluorescein and Rose Bengal scores improved statistically after 7 days of treatment and even more after 90 days. The average Schirmer I and BUT values were unchanged after 7, 14 and 21 days but did show an improvement relative to baseline after 28 days of treatment. Schirmer I, BUT, fluorescein and Rose Bengal did not show any statistical significance in the vehicle group. CONCLUSION: Topical 0.03% tacrolimus eye drop improved tear stability and ocular surface status in cases of inflammatory or SS-related dry eye. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01850979.
Authors: Tulio B Abud; Francisco Amparo; Ujwala S Saboo; Antonio Di Zazzo; Thomas H Dohlman; Joseph B Ciolino; Pedram Hamrah; Reza Dana Journal: Ophthalmology Date: 2016-04-13 Impact factor: 12.079
Authors: Anna M Ambroziak; Jerzy Szaflik; Jacek P Szaflik; Maciej Ambroziak; Jan Witkiewicz; Piotr Skopiński Journal: Cent Eur J Immunol Date: 2016-07-15 Impact factor: 2.085
Authors: Mihir Shah; Maria C Edman; Srikanth Reddy Janga; Frances Yarber; Zhen Meng; Wannita Klinngam; Jonathan Bushman; Tao Ma; Siyu Liu; Stan Louie; Arjun Mehta; Chuanqing Ding; J Andrew MacKay; Sarah F Hamm-Alvarez Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799